Oleanane probe molecules I and their uses
By designing oleanolic acid probe molecule I and cross-linking the fluorophore using click chemistry, we achieved targeted binding and visual localization of Y-box binding protein 1, solving the problem of lacking effective targeted recognition and inhibition of Y-box binding protein 1 in existing technologies, and demonstrating excellent anti-tumor activity.
Patent Information
- Application Number
- CN202410624141.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-20
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-05-20
AI Technical Summary
Existing technologies lack effective small molecule compounds that can target and bind to Y-box binding protein 1, visualize and identify the protein, and possess anti-tumor cell proliferation activity.
A class of oleanane probe molecules I was designed. By cross-linking the fluorophore through a click chemical reaction, it specifically targets the Y-box binding protein 1, blocking its transcriptional function and inhibiting cancer cell proliferation.
Oleanane probe molecule I exhibits good binding activity to Y-box binding protein 1 and tumor cell proliferation inhibition activity. It can visualize the intracellular distribution of Y-box binding protein 1 and has significant anti-tumor effects.
Smart Images

Figure CN118580295B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a class of oleanane probe molecules. The design principle and mechanism of action of the oleanane compound CDDOMe is based on the characteristic of CDDOMe targeting and binding to Y-box binding protein 1. CDDOMe is designed as a probe compound that can be clicked and cross-linked with fluorophores. Background Technology
[0002] Mammalian Y-box binding protein 1 (YBX1), encoded by the YBX1 gene on chromosome 1, is an oncogenic protein capable of binding to DNA / RNA and belongs to the cold shock protein superfamily (Biochemical J, 2013, 449, 11-23). Structure determines function; YBX1 has multiple functions within the cell, inextricably linked to its unique structure. YBX1 comprises three regions: the central cold shock protein binding domain, containing 65 amino acids, is the region capable of binding to DNA / RNA. Therefore, YBX1 participates in various DNA / RNA-dependent events, such as DNA transcription and mRNA splicing; the N-terminal domain is rich in alanine and proline, i.e., the A / P domain; and the C-terminus contains alternating positive and negative charged amino acids, exhibiting hydrophilicity and interacting with intracellular proteins or nucleic acids, serving as a binding site for DNA repair proteins. YBX1 is highly expressed during embryonic development; however, its expression gradually decreases with growth and development. Previous studies have shown that Y-box binding protein 1 is highly expressed in various tumor tissues, including lung cancer, renal cell carcinoma, and breast cancer, and is highly correlated with poor prognosis such as tumor metastasis, recurrence, and drug resistance, making it a potential molecular marker for tumor progression regulation (Int J Cancer, 2016, 139, 433-445). Multiple studies have demonstrated that Y-box binding protein 1 plays an important role in regulating tumor cell proliferation, apoptosis, invasion, and migration. It promotes EMT by activating Snail, Slug, and HIF-1α; induces MMP2 and MMP9 secretion to accelerate cell penetration; and participates in regulating the Wnt / β-Catenin signaling pathway to enhance tumor cell differentiation and metastasis, among other pathways that regulate tumor invasion and metastasis (Nature. 2020, 588, 157-163; Cancer Cell. 2009, 15, 402-415).
[0003] Studies have shown that Y-box binding protein 1 (YBX1) is mainly distributed in the cytoplasm and participates in regulating the expression of various genes related to tumor cell invasion and metastasis. In breast cancer, YBX1 can induce epithelial cell-to-mesenchymal transition (EMT) by directly transcribedly activating Snail, thereby promoting the invasive and metastatic ability of breast cancer cells. Overexpression of YBX1 in non-invasive breast epithelial cells can induce EMT. Ha et al. found that after overexpression of YBX1, TGF-β1 activated AKT, inhibited the expression of E-Cadherin, and upregulated the expression of snail and slug transcription factors, promoting the EMT process of lung cancer cells and promoting the invasion and metastasis of lung cancer (Biochem Biophys Res Commun. 2015, 458(2):347-51). Studies by El-Naggar et al. have shown that Y-box binding protein 1 is highly expressed in various high-risk human sarcomas and can directly bind to HIF-1α mRNA. By enhancing its translation and upregulating its expression, it promotes the metastasis of high-risk sarcomas (Cancer Cell. 2015, 27(5):682-97). Therefore, targeting Y-box binding protein 1 can effectively inhibit lung cancer invasion and metastasis through multiple pathways.
[0004] However, pharmaceutical research targeting this target is still in its early stages, and reports on the development of related small molecule inhibitors are rare. Currently, only the small molecule SU056 has been reported to have potential direct binding activity to Y-box binding protein 1, but specific binding activity data have not been disclosed (Chinese patent CN116761602A). Summary of the Invention
[0005] This invention aims to provide an oleanane probe molecule I that targets and recognizes Y-box binding protein 1 and exhibits good anti-lung cancer activity. Its design principle and mechanism of action utilize an oleanane derivative molecule independently discovered by the inventors, possessing targeted binding activity to Y-box binding protein 1. This molecule is designed as a clickable chemical reaction-enabled probe compound that cross-links with a fluorophore, allowing the compound to specifically locate and emit light at the position of Y-box binding protein 1, thus achieving the function of visually identifying and targeting this protein. Furthermore, probe molecule I can covalently bind to amino acid position 170 (lysine, abbreviated as K) in Y-box binding protein 1. 170 It blocks the transcriptional function of Y-box binding protein 1 and inhibits the proliferation of various cancer cells.
[0006] According to the embodiments, the invention provides a class of oleanane probe molecules I that target and recognize Y-box binding protein 1 and have good anti-tumor cell proliferation activity. Its structure is shown in Formula I, and its chemical name is 2-cyano-3,12-dicarbonyl-oleanane-1(2),9(11)-diene-28-propargyl ester.
[0007]
[0008] The preparation method of the aforementioned oleanane probe molecule I of the present invention is as described in Example 1 below.
[0009] Subsequent examples will demonstrate that the aforementioned oleanolic acid probe molecule I of the present invention not only has good in vitro Y-box binding protein 1 binding activity and tumor cell proliferation inhibition activity, but also can cross-link fluorescent groups through intracellular click reaction to visualize and identify Y-box binding protein 1 and reflect its specific intracellular distribution.
[0010] Compared with the currently reported Y-box binding protein 1 molecules, the oleanane probe molecule I of the present invention has the following significant advantages: (1) The oleanane probe molecule I has good Y-box binding protein 1 binding activity and tumor cell proliferation inhibition activity. (2) There are currently no reports of small molecule compounds that can be visually located for Y-box binding protein 1. Attached Figure Description
[0011] Figure 1 This is the synthetic route diagram for oleanane probe molecule I.
[0012] Figure 2 This is the synthetic route diagram for compound II.
[0013] Figure 3 The results show the concentration-dependent labeling of target proteins by the positive probe with and without CDDO-Me competition, including: (A) in-gel fluorescence scan; (B) Coomassie brilliant blue staining (left) and fluorescence image (right).
[0014] Figure 4 The pull-down assay verifies the target location (A), and the immunoblotting assay verifies the potential target protein (B).
[0015] Figure 5 This indicates that oleanolic acid probe molecule I covalently binds to K of Y-box binding protein 1. 170 .
[0016] Figure 6 The results showed that the oleanolic acid probe molecule I was consistent with the localization of the YBX1 protein in cells.
[0017] Figure 7 The red fluorescence of oleanane probe molecule I was significantly reduced after the intracellular YBX1 protein was knocked down. Detailed Implementation
[0018] The present invention will be further described below with reference to the accompanying drawings and specific embodiments. These embodiments should be understood as illustrative only and not as limiting the scope of protection of the present invention. After reading the description of the present invention, those skilled in the art can make various alterations or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.
[0019] In the following embodiments of the present invention, oleanane probe molecule I is also referred to simply as probe molecule I.
[0020] Example 1 - Synthesis and Characterization of Probe Molecule I
[0021] Dissolve 100 mg (1 eq, 0.196 mM) of CDDO in 3 mL of dichloromethane, then add 1 mL of oxalyl chloride and stir overnight at room temperature. Remove the organic phase by rotary evaporation of the reaction solution to obtain a white solid, which is I. a 10.8 mg (1 eq, 0.196 mM) of propargylamine was dissolved in 2 mL of dichloromethane, and 39.6 mg (2 eq, 0.392 mM) of triethylamine was added. The mixture was stirred at 0 °C. The prepared CDDO-Cl was dissolved in 2 mL of anhydrous dichloromethane and added dropwise to the above reaction solution. The reaction process was monitored by TLC (dichloromethane:methanol = 100:1). After about 2 hours, the starting material CDDO-Cl completely disappeared. An appropriate amount of silica gel was added to the reaction solution, and the organic phase was removed by rotary evaporation under reduced pressure. The solution was then purified by silica gel column chromatography to obtain 72 mg of I (yield 67%). Figure 1 ). 1 H NMR (400MHz, DMSO-d6) δ8.66(s,1H),8.15(t,J=5.6Hz,1H),6.21(s,1H),3.93(ddd,J=17.2,5. 8,2.3Hz,1H),3.77(ddd,J=17.2,5.3,2.4Hz,1H),3.04(d,J=4.6Hz,1H),3.00(t,J=2.3Hz,1H), 2.87(d,J=13.6Hz,1H),2.03–1.50(m,9H),1.43(s,3H),1.40(s,2H),1.38–1.28(m,2H),1.26(s ,3H),1.18(s,3H),1.12(d,J=20.0Hz,2H),1.07(s,3H),0.94(s,3H),0.90(s,3H),0.86(s,3H). 13C NMR(101MHz,DMSO-d6)δ199.66,197.78,176.86,169.53,168.79,123.81,115.58,11 3.28,82.37,72.47,49.12,46.66,45.90,44.84,43.02,41.99,35.75,34.54,33.70, 33.30,31.66,31.30,30.69,28.64,27.66,26.81,26.58,26.30,25.00,23.60,22.23 ,21.77,21.60,17.95.HRMS:C34H44N2O3(M+H)Calcated:529.3431,found:529.3426
[0022] Example 2 - Synthesis and Characterization of Negative Control Compound II
[0023] 50 mg (1 eq, 0.095 μmol) of compound I was dissolved in 3 mL of methanol, followed by the addition of 7.2 mg sodium borohydride (2 eq, 0.19 μmol). The reaction was monitored by thin-layer chromatography. After the starting material was consumed, saturated ammonium chloride was added to the reaction solution, followed by extraction three times with ethyl acetate. The organic phases were combined, silica gel was added, and the organic phase was removed by rotary evaporation. The solution was then purified by silica gel column chromatography (dichloromethane:methanol = 40:1) to obtain 22 mg of compound II (yield 44%). Figure 2 ). 1H NMR (400MHz, DMSO-d6) δ8.13(t,J=5.5Hz,1H),5.60(s,1H),5.48(d,J=4.4Hz,1H),3.96–3.87(m,1H),3.75(ddd,J=17.2,5.2,2.4Hz,1H),3.26(t,J= 5.0Hz,1H),3.23–3.19(m,1H),3.00(q,J=2.6Hz,1H),2.96(d,J=4.7Hz,1H ),2.84(d,J=13.5Hz,1H),2.29(t,J=11.6Hz,1H),1.89(t,J=13.2Hz,1H), 1.62(dd,J=17.2,10.8Hz,5H),1.56(d,J=4.5Hz,2H),1.53(d,J=3.3Hz,1H ),1.43(s,3H),1.34(d,J=15.1Hz,2H),1.29–1.24(m,1H),1.21(s,3H),1. 17(s,1H),1.14(s,2H),1.05(d,J=11.0Hz,1H),0.99(d,J=1.9Hz,3H),0.9 8–0.98(m,1H),0.91(d,J=6.3Hz,3H),0.89(s,3H),0.86(d,J=2.8Hz,3H).
[0024] Example 3 - In-gel fluorescence assay shows that probe molecule I binds to the protein in the band containing Y-box binding protein 1.
[0025] ☆Experimental steps: (1) Seed A549 cells in good growth condition at a density of 400,000 cells / well into 6cm culture dishes. After overnight culture, the cells adhered to the culture dish. Add the drug solution with a set concentration gradient. After incubating the drug with the cells for 24 hours;
[0026] (2) Collect the cell suspension and transfer it to a labeled 1.5 mL centrifuge tube. Centrifuge at 1500 rpm for 5 min to collect the cell pellet. Lyse the cells and collect the cell supernatant. Place the supernatant on ice. Adjust the protein concentration with cell lysis buffer according to the protein quantification results.
[0027] (3) Prepare the click reaction solution. Prepare it fresh and use it immediately. Prepare the total reaction solution according to the molar ratio of probe, TAMRA-N3, TBTA, TCEP and CuSO4 of 1:2:5:50:50. Add 3.4 μL of click reaction solution to every 200 μL of system and react in the dark on a shaker at room temperature for 2 hours.
[0028] (4) Add 5×loading to the cell lysis buffer, mix well, boil in a metal bath at 100℃ for 10 min, and perform protein gel electrophoresis; use Typhoon FLA 9500 for gel imaging.
[0029] ★Experimental Results: The protein band containing Y-box-binding protein 1 in the molecular weight range of 40–75 kDa not only exhibited significant fluorescence release, but its intensity also increased with the increasing concentration gradient of probe molecule I. In the control / competitive group, the fluorescence intensity of this band was significantly weakened due to its competitive binding to the target protein by probe molecule I. The weakening fluorescence of the negative compound II further corroborated this change in this region. Figure 3 The probe molecule is P1 in the figure (the same applies below).
[0030] Example 4 - Pull-down assay to evaluate the binding of compound I to Y-box binding protein 1 in cells.
[0031] ☆Experimental steps: (1) A549 cells in the logarithmic growth phase were seeded into 6cm culture dishes at a density of 400,000 cells / well. The cells were cultured overnight and adhered to the wall. Drug solutions with a set concentration gradient were added and incubated for 24 hours.
[0032] (2) Lyse cells and add click reaction solution (prepared with PBS to a final concentration of 20 μM TAMRA-N3, 50 μM TBTA, 500 μM TCEP, and 500 μM CuSO4) for Click reaction. Quantify protein using the BCA method. Transfer 16 μL of supernatant to a new EP tube, add 5× loading solution, and boil in a 100°C metal bath for 5 minutes as the input protein.
[0033] (3) Place the Capturem Streptavidin Miniprep column into a 2mL centrifuge tube, add equilibration buffer and centrifuge. Add the supernatant to the column, centrifuge, and collect the filtrate. Add elution buffer to the column, centrifuge, and collect the filtrate. Prepare a new labeled 1.5mL centrifuge tube and add 10μL of neutralization buffer. Transfer the column to the 1.5mL centrifuge tube containing the neutralization buffer, add 90μL of elution buffer for elution (the 1.5mL centrifuge tube contains a total of 100μL of liquid), and collect the elution buffer.
[0034] (4) The collected eluent was used to quantify the protein and was used as a pull-down protein sample; protein gel electrophoresis was performed, and the gel was silver stained according to the Beyotime silver staining kit instructions; the gel was cut off and sent to the company for protein spectrum detection, and the protein bound to the probe was obtained by comparison and analysis with the existing protein database, and data statistics and bioinformatics analysis were performed.
[0035] ★Experimental Results: Further pull-down assays showed band positions consistent with those in the gel fluorescence imaging results described above, indicating that this band represents the location of the CDDO-Me potential target protein, Y-box binding protein 1. Protein proteometry analysis identified over 2000 proteins. Proteins from the mass spectrometry analysis results were screened based on the following criteria:
[0036] (1) The protein abundance in the blank group was zero, and 100 proteins were obtained by screening.
[0037] (2) Continue screening among these 100+ proteins. The abundance value of the protein bound by probe molecule I is greater than that of the protein in the competing group.
[0038] (3) Compound II had the lowest protein abundance value. Finally, the groups were ranked according to the fold change in protein abundance, with higher fold changes ranking higher. Eight proteins were found to be highly correlated with tumor invasion and metastasis. Immunoblotting was performed on these eight proteins, revealing that only Y-box binding protein 1 showed a consistent trend. Specifically, the protein expression level in the compound I treatment group was higher than that in the blank group and the negative probe administration group, and the protein level in the competition group also decreased, suggesting that Y-box binding protein 1 is the binding target protein of probe molecule I. Figure 4 ).
[0039] Example 5 - Mass spectrometry analysis results show that probe molecule I covalently binds to the K of Y-box binding protein 1. 170 Location
[0040] ☆Experimental steps: (1) Take about 2 μg of YBX1 protein and incubate with probe molecule I at a final concentration of 7 μM at 37℃ for 12 h. Add DTT to a final concentration of 2 mM, place at room temperature for 10 min, and heat at 95℃ for 30 s to terminate the reaction. Add 0.2 μg of trypsin and digest at 37℃ for 16 h. Desalt the digested peptides and evaporate to dryness under vacuum.
[0041] (2) LC-MS / MS detection and analysis: The evaporated peptides were dissolved in 0.1% formic acid and injected into a reversed-phase C18 column (20 cm long × 75 μm inner diameter, 1.9 μm particle size). Separation was performed using an EASY-nLC 1200 ultra-high performance liquid chromatography system coupled with a mass spectrometer. Gradient elution was performed within 30 min using solvent B (A, 0.1% formic acid solution; B, 0.1% formic acid solution containing 80% acetonitrile) from 5% to 90%.
[0042] (3) Mass spectrometry was performed in positive ion mode, and primary mass spectra (mass range from m / z 350 to 1350) were acquired in Orbitrap at a resolution of 60,000. Automatic gain control (AGC) was set to 1e6. For each primary mass spectrum scan, the 10 most abundant ions were selected, and secondary mass spectra were acquired in Orbitrap at a resolution of 30,000. AGC was set to 2e5, the maximum injection time was 100 ms, and the normalized collision energy was 28.
[0043] (4) The raw data were analyzed using MaxQuant (version 2.0.3.1) and compared with the UniProt human database (released in January 2020). Trypsin / P was selected as the digestive enzyme, and two uncut sites were allowed. Experimental results: as shown Figure 5 As shown, probe molecule I covalently binds to the K of Y-box binding protein 1. 170 Location.
[0044] Example 6 - Micro-thermophoretic MST experiment shows that probe molecule I interacts with γ-box binding protein 1.
[0045] ☆Experimental Procedure: (1) Use the His-Tag Labeling Kit RED-trisNTA 2 protein labeling kit nd The recombinant tagged His-GFP-YBX1 protein was labeled using Generation (MO-l018, Nano Temper); 8 ml of ddH2O was added to a 5×PBS-T bottle to dilute it to 1×PBS-T.
[0046] (2) Add 25 μL of PBS-T to the dye and dilute the dye to 5 μM. Take 2 μL of dye and add it to 98 μL of PBS-T and dilute the dye to 100 nM. Dilute the recombinant protein (initial concentration is 0.3 mg / mL, final concentration is 200 nM). Mix the protein and dye at a 1:1 ratio and incubate at room temperature for 30 min. Centrifuge at 12,000 rpm at 4℃ for 10 min and transfer the supernatant to a new EP tube.
[0047] (3) Label the PCR tubes in order, add 10 μL of the corresponding concentration of drug solution to the PCR tube, then add 10 μL of protein sample, so that the final concentration of Y-box binding protein 1 solution is 50 nM. Vortex vigorously for 10 s, centrifuge, incubate at room temperature for 15 min, and detect the K+ binding of protein and drug using the MST instrument and MO.Control. d value.
[0048] ★Experimental Results: K of probe molecule I d =2-4 μmol / L (results from three replicates).
[0049] Example 7 - Fluorescence colocalization assay showed that probe molecule I and Y-box binding protein 1 were congruently localized within cells.
[0050] ☆Experimental steps: (1) A549 cells in the logarithmic growth phase were seeded into confocal microplates at a density of 50,000 cells / plate and allowed to adhere overnight; probe molecule I was added to the confocal microplates and incubated for 3 hours; 300 μL of 4% paraformaldehyde was added to the confocal microplates to fix the cells, and the cells were fixed at room temperature for 30 minutes and then washed with PBS; 300 μL of PBS containing 0.1% Triton X-100 was added to the confocal microplates, and the cells were treated for 15 minutes and then washed with PBS.
[0051] (2) Prepare 2% BSA and block at room temperature for 1 hour; according to the instructions for use of the primary antibody, dilute the YBX1 antibody with 2% BSA at a ratio of 1:200, add it to the confocal dish, and incubate overnight; recover the primary antibody, select the secondary antibody according to the required color and resistance (488 is green, Cy3 is red), dilute the secondary antibody at a ratio of 1:500, incubate at room temperature in the dark for 1 hour, discard the secondary antibody, and wash 3 times with PBS;
[0052] (3) Prepare the Click reaction solution: Prepare a mixture of 20 μM TAMRA-N3, 50 μM TBTA, 500 μM TCEP, and 500 μM CuSO4 in PBS. Perform the Click reaction at room temperature on a shaker in the dark for 2 hours. Wash away any residual Click reaction solution with PBS at 40 rpm for 5 minutes each time. For the last wash, replace the solution with 0.1% Tween 20 and wash for 5 minutes or longer on a shaker. Prepare the nuclear staining solution using DAPI or hochest according to the manufacturer's instructions (prepared in PBS containing 2% BSA). Stain in the dark for 15 minutes. Take pictures using a confocal microscope.
[0053] ★Experimental Results: (e.g.) Figure 6 As shown, probe molecule I is mainly distributed in the cytoplasm (red fluorescence), and Y-box binding protein 1 is also distributed in the cytoplasm (green fluorescence). The overlap of their merge states (yellow fluorescence) was quantitatively analyzed using ImagJ software. The analysis showed that the fusion coefficient of probe molecule I and Y-box binding protein 1 was 0.7 (Rcolor value). This data indicates that CDDO-Me and Y-box binding protein 1 are basically distributed in the cell (a higher Rcolor value indicates a higher overlap rate; Rcolor = 1 indicates complete overlap, and Rcolor > 0.6 indicates high overlap).
[0054] Example 8 - After knocking down YBX1, probe molecule I lost its intracellular localization effect.
[0055] ☆Experimental Procedure: Replace normal A549 cells with A549 cells with YBX1 protein knocked down, and follow the same procedure as described in Example 7.
[0056] ★Experimental Results: (e.g.) Figure 7 As shown, the green fluorescence of Y-box binding protein 1 weakens after being knocked down in the cell, and the red fluorescence emitted by the same probe molecule I after the click reaction also weakens significantly, further indicating that probe molecule I targets and binds to Y-box binding protein 1.
[0057] Example 9 - Evaluation of the tumor cell proliferation inhibitory activity of probe molecule I using the CCK8 assay
[0058] ☆Experimental Procedure: 1) Cell Plating: Take tumor cells in the logarithmic growth phase, digest them with trypsin, centrifuge at 1000 rpm for 1 min, discard the supernatant, resuspend the cells in culture medium, count them using a cell counting chamber, dilute the cells with culture medium and add them to 96-well plates. The cell plating density is: A549: 2000-2500 cells / well; TCMK-1: 2000-2500 cells / well, 100 μL / well, 3 replicates. Add 200 μL of PBS to the outermost well of the 96-well plate and incubate overnight at 37°C.
[0059] 2) Drug treatment: Discard the culture medium and add 100 μL of culture medium containing different final concentrations of probe molecules (100, 33, 11, 3.7, 1.2, 0.4, 0.14, 0.04 and 0 μM) to each well. Incubate in an incubator for 72 h.
[0060] 4) Absorbance Measurement and Data Processing: After incubation, the culture medium was discarded, the cells were washed with PBS, and a reaction solution containing 10% CCK-8 prepared with the culture medium was added. The cells were then incubated for another 40 minutes. The absorbance at 450 nm was measured using a microplate reader, and the inhibitory activity (IC50) of the target compound against tumor cell proliferation was calculated using GraphPad 9.0 software. 50 value).
[0061] ★Experimental results: See Table 1.
[0062] Table 1. Evaluation of the inhibitory activity of probe molecule I on the proliferation of various tumor cells
[0063]
[0064] In summary, the probe molecule I of this invention exhibits excellent YBX1 protein recognition and potential anti-tumor activity both in vitro and in vivo. It is suitable for developing therapeutic anti-tumor drugs targeting YBX1, YBX1 detection kits, or diagnostic products related to diseases or indications caused by YBX1. Currently, no similar compounds have been reported, demonstrating significant novelty, originality, and practicality.
Claims
1. The oleanane probe molecule I shown in Formula I, 2. The use of the oleanane probe molecule I according to claim 1 in the preparation of probes that target and bind to YBX1.
3. The use as described in claim 2, characterized in that, Oleanane probe molecule I targets and binds to YBX1, and through a click reaction, crosslinks with azide-containing fluorescent groups, enabling it to be visualized and recognized within cells, and its distribution can be located.
4. The use as described in claim 3, characterized in that, The distribution of YBX1 in cells was directly observed using a fluorescence microscope.
5. The use of the oleanolic acid probe molecule I according to claim 1 in the preparation of a drug for treating tumors, wherein the oleanolic acid probe molecule I inhibits the growth of tumor cells, said tumor cells being human lung cancer cells, human liver cancer cells, human gastric cancer cells, human colorectal cancer cells, or human breast cancer cells.
Citation Information
Patent Citations
Medical application of oleanolic acid
CN112546050A
Y-cartridge binding protein 1
CN116761602A
